Latest Biotech News

Two legal and regulatory developments touched Guardant Health this week. The US Court of Appeals remanded a patent‑infringement dispute between Guardant, TwinStrand Biosciences and the University...

Corcept Therapeutics reported a Phase III Rosella trial result showing relacorilant added to chemotherapy produced a 35% reduction in risk of death in platinum‑resistant ovarian cancer, meeting a...

Researchers at the Icahn School of Medicine at Mount Sinai reported preclinical results in Cancer Cell showing IL‑12‑producing CAR T cells designed to target tumor‑associated macrophages (TAMs)...

Two mechanistic cancer studies outlined how tumors evade therapy and immune detection. A Cell paper showed high‑MYC tumors suppress innate immune signaling by binding nascent RNA and recruiting...

The National Institutes of Health announced it would end support for research using fetal human tissue, a policy shift critics call political rather than scientific. The termination affects...

NVIDIA and Eli Lilly announced a $1 billion collaboration to build an AI‑powered drug discovery laboratory in the San Francisco Bay Area. The pact combines NVIDIA’s computing and AI stack with...

Guardant Health received FDA approval for its Guardant360 CDx as a companion diagnostic to guide use of Pfizer’s Braftovi‑cetuximab chemotherapy regimen for BRAF V600E colorectal cancer, while a...

Corxel Pharmaceuticals closed a $287 million Series D to propel its oral small‑molecule GLP‑1 receptor agonist CX‑11 through ongoing U.S. phase II studies and planned global trials, and to prepare...

Sanofi said it will pursue global regulatory submissions for amlitelimab in atopic dermatitis despite mixed Phase 3 results. One pivotal study met primary and key secondary endpoints, while a...

Bristol Myers Squibb struck an exclusive collaboration and license with Janux Therapeutics to develop a tumor‑activated therapeutic derived from Janux’s TRACTr platform, with up to $850 million in...

Researchers at the Icahn School of Medicine at Mount Sinai reported preclinical data showing IL‑12–producing CAR T cells targeted to tumor‑associated macrophages (TAMs) reprogram the tumor...

A*STAR researchers identified a membrane‑proximal survival mechanism that stabilizes mutant EGFR in non‑small cell lung cancer: extracellular ATP activates the P2Y2 receptor, which recruits...

Corcept Therapeutics reported that relacorilant, an oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in a Phase 3 study for platinum‑resistant ovarian cancer,...

San Diego protein‑sequencing company Encodia ceased operations and began auctioning laboratory equipment after filing an assignment for the benefit of creditors in California. The collapse halts...

The J. Craig Venter Institute announced a new spinout, Diploid Genomics, launching with seed support from Healthier Capital to build an AI‑driven genomics analytics platform for research and...

NVIDIA and Eli Lilly announced a $1 billion collaboration to build an AI-powered drug discovery laboratory in the San Francisco Bay Area. The pact will combine NVIDIA’s computing platforms with...

The U.S. Food and Drug Administration approved Guardant Health’s Guardant360 CDx as a companion diagnostic to identify BRAF V600E‑mutant metastatic colorectal cancer patients for Pfizer’s...

Bristol Myers Squibb agreed an exclusive collaboration and licensing deal with Janux Therapeutics for a tumor‑activated T‑cell engager program, paying $50 million up front with potential...

Corcept Therapeutics reported Phase 3 data showing that relacorilant added to chemotherapy reduced risk of death by 35% in platinum‑resistant ovarian cancer, meeting a prespecified overall...

Corxel Pharmaceuticals closed a $287 million Series D to advance CX‑11, an oral small‑molecule GLP‑1 receptor agonist licensed from Vincentage, through ongoing U.S. Phase II obesity trials and...